Welcome to our dedicated page for SL Science Holding SEC filings (Ticker: SLBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SL Science Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SL Science Holding's regulatory disclosures and financial reporting.
SL Science Holding Ltd director Xu Qian has filed an initial Form 3, reporting direct ownership of 20,000 Ordinary Shares of SL Science Holding Ltd. This filing establishes Xu Qian’s reported equity position as an insider and does not disclose any recent share purchases or sales.
SL Science Holding Ltd filed an initial Form 3 for Johnson Shun-Pong Lau, who serves as Vice President of Finance. The filing reports his status as an officer but does not list any specific share holdings or transactions in company securities.
SL Science Holding Ltd director and Chief Technology Officer Ethan Shen, PhD has filed an initial Form 3 ownership report as an insider of the company. The filing does not report any share purchases, sales, option exercises, or other equity transactions at this time.
SL Science Holding Ltd filed an initial Form 3 for director Liu Mingche. This filing serves as the first statement of beneficial ownership for this insider and establishes a baseline record of their reporting status with no transactions disclosed in this document.
SL Science Holding Ltd director Chen Kwo-Liang has filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The filing lists his status as a director of the company but does not report any current holdings or recent transactions in SLBT securities.
SL Science Holding Ltd director General John Conrad filed an initial ownership report on Form 3. This filing identifies him as a director and reporting person for SLBT but shows no reported stock or derivative holdings and no buy, sell, or other insider transactions.
SL Science Holding Ltd filed an initial Form 3 for Chief Financial Officer Leung Lok Sang. This filing reports no insider transactions or derivative positions, with all buy, sell, exercise, and other transaction counts shown as zero in the summary data.
SL Science Holding Ltd filed a Form 3 for director Joseph Levinson, which is an initial statement of beneficial ownership for insiders. The filing’s transaction summary shows no buys, sells, gifts, exercises, or other transactions and no derivative positions in this excerpt.
SL Science Holding Limited has completed its business combination between SL BIO Ltd. and Horizon Space Acquisition II Corp., creating a Cayman Islands holding company whose ordinary shares are expected to begin trading on the Nasdaq Global Market under the ticker “SLBT” on June 15, 2026.
The transaction carries an implied equity valuation for SL Bio of approximately $5.568 billion and includes a concurrent $7.8 million PIPE financing, providing additional capital for its cell and gene therapy platform. SL Science has also installed a public‑company leadership team, led by CEO William Wang and CFO Ray Leung, and formed a board with multiple independent directors experienced in accounting, investment banking, regulatory compliance, and scientific oversight.